Wainua, an investigational medication for the treatment of familial hypercholesterolemia, was launched in the United States on March 27, 2024. [1]
What is Wainua and how does it work?
Wainua is a novel oral medication designed to lower LDL cholesterol. It functions by inhibiting the protein PCSK9, which plays a role in regulating LDL cholesterol levels in the liver. By blocking PCSK9, Wainua increases the number of LDL receptors on the liver surface, leading to more efficient removal of LDL cholesterol from the blood. [1]
What conditions is Wainua approved to treat?
Wainua is approved in the United States for the treatment of adults and adolescents 12 years of age and older with homozygous familial hypercholesterolemia (HoFH). [1]
What is homozygous familial hypercholesterolemia (HoFH)?
Familial hypercholesterolemia is a genetic disorder characterized by very high levels of LDL cholesterol, often referred to as "bad" cholesterol, from birth. HoFH is the more severe form of the condition, where both copies of the involved gene are affected, leading to extremely elevated LDL cholesterol and a high risk of premature cardiovascular disease. [2]
How does Wainua compare to other cholesterol-lowering treatments?
Wainua offers a different mechanism of action compared to traditional statins. While statins also aim to lower LDL cholesterol, Wainua targets the PCSK9 pathway, which can provide an additional reduction in LDL-C levels. Other PCSK9 inhibitors are available as injectable medications, making Wainua the first oral PCSK9 inhibitor for HoFH. [1][3]
When does Wainua's patent protection expire?
Information regarding Wainua's specific patent expiration dates is not publicly available in the provided text. DrugPatentWatch.com tracks patent information for medications, which can be a resource for detailed patent and exclusivity timelines. [4]